Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.2219 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.2617 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.2777 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.2866 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.3417 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.3434 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.3441 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.3580 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.3709 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.3922 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.4036 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.4654 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.4713 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.4744 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5023 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5150 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5226 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5351 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5431 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5468 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5470 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5547 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5757 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.5882 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6057 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6126 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6179 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6182 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6408 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6434 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6465 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6561 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6580 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6684 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6744 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6870 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6891 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6909 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6945 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.6979 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7013 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7035 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7168 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7296 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7371 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7482 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7491 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7541 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7575 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7606 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7638 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7707 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7742 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7835 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7884 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7898 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7908 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.7996 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8045 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8202 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8241 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8289 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8302 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8315 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8329 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8487 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8493 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8507 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8536 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8537 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8648 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8664 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8698 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8704 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8719 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8734 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8737 | scaled units | Low-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8754 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8826 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8836 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8874 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8882 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8909 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8960 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.8963 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9170 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9202 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9261 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9785 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9859 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9897 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9935 | scaled units | High-Dose | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 0.9984 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0000 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0001 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0016 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0079 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0081 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0265 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0281 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0325 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0337 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0536 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0546 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0602 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0697 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0752 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0757 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0781 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0824 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0846 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0863 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0899 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0927 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.0986 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1045 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1137 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1263 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1296 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1346 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1366 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1483 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1572 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1668 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1682 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1844 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1919 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.1972 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2046 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2152 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2160 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2233 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2350 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2465 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2539 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2723 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2794 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2798 | scaled units | Placebo | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2835 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2861 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2863 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2893 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.2939 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3022 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3075 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3106 | scaled units | Low-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3289 | scaled units | High-Dose | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3314 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3372 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3419 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3466 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3511 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3568 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3584 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3629 | scaled units | Placebo | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3687 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3831 | scaled units | High-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.3832 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.4032 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.4352 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.4645 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.4667 | scaled units | Low-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.4781 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.5143 | scaled units | Placebo | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.5238 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.5311 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.5316 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.5421 | scaled units | Low-Dose | +71HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.5544 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.6017 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.7135 | scaled units | Placebo | +4HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.7226 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.7864 | scaled units | High-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8087 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8128 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8241 | scaled units | High-Dose | +23HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8553 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8554 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8617 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.8983 | scaled units | Placebo | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 1.9974 | scaled units | High-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 2.0327 | scaled units | Low-Dose | +47HR POST INFUSION |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 2.1044 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 2.1540 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 2.1599 | scaled units | Placebo | BASELINE |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 2.3184 | scaled units | Low-Dose | -0.5HR |
Reversed phase NEGATIVE ION MODE | palmitate (16:0) | 2.4133 | scaled units | Placebo | +4HR POST INFUSION |